Aanhoudende kweekconversie bij refractaire ‘M. avium’ met amikacine-formularium

Delen via:
ATS 2019

Log hier in om volledige toegang te krijgen.

Login of Account maken

 

Bronnen:
Griffith DE, Thomson R, Addrizzo-Harris DJ, et al. Sustainability and durability of culture conversion in patients receiving amikacin liposome inhalation suspension (ALIS) for treatment-refractory mycobacterium avium complex lung disease (MAC-LD) in the CONVERT Study. Am J Resp Crit Care Med. 2019;199:A7358.